Hong-Yan Zhai1,2, Ping Liang1, Jie Yu1, Feng Cao3, Ming Kuang4, Feng-Yong Liu5, Fang-Yi Liu1, Xin-Yuan Zhu6. 1. Department of Interventional Ultrasound, The General Hospital of Chinese People's Liberation Army, Beijing, China. 2. Department of Ultrasound, Tianjin Medical University General Hospital, Tianjin, China. 3. Department of Cardiovascular, The General Hospital of Chinese People's Liberation Army, Beijing, China. 4. Department of Medical Ultrasound, Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. 5. Department of Interventional Radiology, The General Hospital of Chinese People's Liberation Army, Beijing, China. 6. Department of Cardiovascular Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Abstract
OBJECTIVE: This study aimed to compare the efficacy of Sonazoid and SonoVue in subjects with focal liver lesions. METHODS: The patients who had untreated focal solid liver lesions confirmed by B-mode ultrasonography were eligible for the study. The target lesion and whole liver were scanned by gray scale ultrasonography; then, contrast-enhanced ultrasonography was performed, and the results were evaluated blindly. The main end point was accuracy improvement with postcontrast versus precontrast ultrasound examination for diagnosis of the target lesion of interest as malignant or benign against the reference standard. RESULTS: There were 65 patients with 65 hepatic tumors enrolled in the study. The improvement of diagnostic accuracy was 0.30 in the Sonazoid group and 0.16 in the SonoVue group (95% confidence interval, -0.828-0.168; P = .24). Using 20% as the noninferiority margin, the upper limit of the 95% confidence interval (0.168) was less than 0.20. The number of lesions detected during the whole-liver scanning in the Sonazoid group was significantly more than that detected in the SonoVue group (P = .024). CONCLUSION: The diagnosis value of Sonazoid is noninferior to SonoVue, and this new contrast agent can improves the whole-liver image quality.
OBJECTIVE: This study aimed to compare the efficacy of Sonazoid and SonoVue in subjects with focal liver lesions. METHODS: The patients who had untreated focal solid liver lesions confirmed by B-mode ultrasonography were eligible for the study. The target lesion and whole liver were scanned by gray scale ultrasonography; then, contrast-enhanced ultrasonography was performed, and the results were evaluated blindly. The main end point was accuracy improvement with postcontrast versus precontrast ultrasound examination for diagnosis of the target lesion of interest as malignant or benign against the reference standard. RESULTS: There were 65 patients with 65 hepatic tumors enrolled in the study. The improvement of diagnostic accuracy was 0.30 in the Sonazoid group and 0.16 in the SonoVue group (95% confidence interval, -0.828-0.168; P = .24). Using 20% as the noninferiority margin, the upper limit of the 95% confidence interval (0.168) was less than 0.20. The number of lesions detected during the whole-liver scanning in the Sonazoid group was significantly more than that detected in the SonoVue group (P = .024). CONCLUSION: The diagnosis value of Sonazoid is noninferior to SonoVue, and this new contrast agent can improves the whole-liver image quality.
Authors: Constantin Arndt Marschner; Johannes Rübenthaler; Matthias Frank Froelich; Vincent Schwarze; Dirk-André Clevert Journal: Ultrasonography Date: 2020-11-19
Authors: Qiong Wu; Yilun Liu; Di Sun; Yan Wang; Xiaoer Wei; Jing Li; Beibei Liu; Shuhao Wang; Yan Zhou; Haiyan Hu; Rui Zhang; Qiong Jiao; Yi Li; Tao Ying Journal: Front Med (Lausanne) Date: 2022-08-09